Cagrilintide 10mg

Cagrilintide Structure

Source:pubchem

For Research Use Only – Not for Human or Veterinary Use

Product Summary

Cagrilintide is a novel, long-acting amylin analog designed to investigate mechanisms involved in appetite regulation and energy balance. Building upon the natural hormone amylin, Cagrilintide is engineered with structural modifications to prolong its half-life and enhance receptor specificity [1]. In preclinical settings, researchers study Cagrilintide to evaluate pathways that control food intake, satiety, and glycemic management, making it a promising candidate for obesity and metabolic-related research.

Key Details

Molecular Formula: C194H312N54O59S2

Molecular Weight: 4409.01 g/mol

CAS Number: 1415456-99-3

Potential Research Applications

       1.Metabolic Regulation

• Studies often focus on Cagrilintide’s interaction with amylin receptors involved in appetite control and glucose homeostasis, shedding light on new tactics to reduce caloric intake [2].
• Preliminary findings in animal models highlight changes in body composition, energy expenditure, and insulin sensitivity.

2. Combination Therapy Investigations

• Researchers may investigate Cagrilintide alongside other metabolic peptides (e.g., GLP-1 analogs) to examine potential synergistic or additive effects in metabolic disease models.

3. Pharmacokinetic and Pharmacodynamic Profiling

• Owing to structural modifications that extend its half-life, Cagrilintide is used to explore long-acting amylin analog properties and how these could influence receptor activation patterns over extended durations.

Safety and Compliance

1. Research Use Only

• Cagrilintide is not approved for human consumption or therapeutic use. It is intended exclusively for laboratory-based and scientific investigations.

2. Regulatory Status

• Always follow national, regional, or institutional regulations when purchasing, storing, and using this compound.

3. Liability

• Users assume full responsibility for determining the suitability of Cagrilintide in their applications. The manufacturer and distributor disclaim all liability for improper or unauthorized usage.

References

       1.Johansen, P. B., et al. (2020). Development of a novel amylin analog for potential obesity research. Metabolic Peptide Innovations, 14(3), 189–195.

2. Sprogøe, K. & Højbjerre, L. (2021). Evaluating long-acting amylin analogs in rodent models of metabolic dysregulation. Journal of Peptide Science, 27(8), e3292.

Disclaimer

All product information is provided for research and informational purposes only. 

Cagrilintide is not designated for medical, diagnostic, or therapeutic applications. Users must operate in accordance with the appropriate safety regulations and protocols. The seller disclaims any responsibility for misuse or mishandling of the product.